CD73 expression in the tumor microenvironment has been investigated as a predictive biomarker for clinical outcomes in a variety of tumor types, with a statistically significant correlation between high CD73 expression and poor clinical results [87]. The gene discussed is NT5E; the disease is neoplasm.